肠道菌群
小檗碱
肾
肾脏疾病
微生物学
医学
透析
化学
生物
药理学
生物化学
内科学
作者
Li-Bin Pan,Hang Yu,Jie Fu,Jiachun Hu,Hui Xu,Zhengwei Zhang,Meng-Meng Bu,Xinyu Yang,Haojian Zhang,Jin-Yue Lu,Jian‐Dong Jiang,Yan Wang
标识
DOI:10.1016/j.apsb.2022.12.010
摘要
At present, clinical interventions for chronic kidney disease are very limited, and most patients rely on dialysis to sustain their lives for a long time. However, studies on the gut-kidney axis have shown that the gut microbiota is a potentially effective target for correcting or controlling chronic kidney disease. This study showed that berberine, a natural drug with low oral availability, significantly ameliorated chronic kidney disease by altering the composition of the gut microbiota and inhibiting the production of gut-derived uremic toxins, including p-cresol. Furthermore, berberine reduced the content of p-cresol sulfate in plasma mainly by lowering the abundance of g_Clostridium_sensu_stricto_1 and inhibiting the tyrosine-p-cresol pathway of the intestinal flora. Meanwhile, berberine increased the butyric acid producing bacteria and the butyric acid content in feces, while decreased the renal toxic trimethylamine N-oxide. These findings suggest that berberine may be a therapeutic drug with significant potential to ameliorate chronic kidney disease through the gut-kidney axis.
科研通智能强力驱动
Strongly Powered by AbleSci AI